Elevated SIRT6 levels have been reported in pancreatic (Bauer et al., 2012), breast (Khongkow et al., 2013) and prostate (Liu et al., 2013b) carcinomas where SIRT6 contributes to cell migration, enhanced cell viability and chemotherapeutic resistance. The gene discussed is SIRT6; the disease is carcinoma.